More Mayne Pharma Group Ltd. news
Mayne Pharma Group Ltd.ASX: MYX

Mayne Pharma submits NDA for E4/DRSP to the FDA

Apr 15, 2020 at 10:59 PM EDT · Issued by Mayne Pharma Group Ltd.

Filed with ASX · Apr 15, 2020 at 10:59 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/mayne-pharma-submits-nda-for-e4drsp-to-the-fda

Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26↗

Mayne Pharma Group Ltd. on 6ix

Story so far

  • MYX signs license agreement for novel oral contraceptiveOct 2, 2019
  • FDA approval of Tolsura (SUBA-itraconazole) capsulesDec 12, 2018
  • SUBA-Itraconazole NDA accepted for review by US FDAMay 2, 2018

Earlier from Mayne Pharma

  • 2020 Half Year Investor PresentationFeb 20, 2020
  • 2020 Half Year Media ReleaseFeb 20, 2020
  • 2019 AGM CEOs SpeechNov 21, 2019
  • E4/DRSP contraceptive presented at EU gynecology conferenceOct 22, 2019
  • MYX signs license agreement for novel oral contraceptiveOct 1, 2019

Later from Mayne Pharma

  • MYX signs license agreement for contraceptive in AustraliaMay 28, 2020
  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • MYX announces FDA filing acceptance of E4/DRSP in the USJun 23, 2020
  • Mayne Pharma announces strategic partnership with NovastJul 5, 2020
  • 2020 Full Year Media ReleaseAug 20, 2020
All Mayne Pharma news releases↗

Follow Mayne Pharma into a list and get an email when it puts out news.

Follow Mayne Pharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer